MX2009003771A - Robust sustained release formulations. - Google Patents
Robust sustained release formulations.Info
- Publication number
- MX2009003771A MX2009003771A MX2009003771A MX2009003771A MX2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A
- Authority
- MX
- Mexico
- Prior art keywords
- sustained release
- release formulations
- formulations
- robust
- robust sustained
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these foϿnulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with alcohol. The formulations are useful for treating a patient suffering from a condition, e.g., pain. The formulations comprise at least one drug. In one embodiment, the drug is an opioid, e.g., oxymorphone.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2006/039923 WO2008045060A1 (en) | 2006-10-10 | 2006-10-10 | Robust sustained release formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009003771A true MX2009003771A (en) | 2009-07-22 |
Family
ID=38048029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009003771A MX2009003771A (en) | 2006-10-10 | 2006-10-10 | Robust sustained release formulations. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2079453A1 (en) |
JP (1) | JP5422388B2 (en) |
KR (1) | KR20090113243A (en) |
CN (1) | CN101578096A (en) |
AU (1) | AU2006349402A1 (en) |
BR (1) | BRPI0621947A2 (en) |
CA (1) | CA2652981C (en) |
IL (1) | IL198168A0 (en) |
MX (1) | MX2009003771A (en) |
WO (1) | WO2008045060A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1268338C (en) | 2001-07-06 | 2006-08-09 | 恩德制药公司 | Oral administration of 6-hydroxy-oxymorphone for use as antalgesic |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE102004032049A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
MX2012000369A (en) | 2009-07-22 | 2012-02-01 | Gruenenthal Gmbh | Tamper-resistant dosage form for oxidation-sensitive oploids. |
RU2604676C2 (en) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Destruction-resistant dosage form containing an inorganic salt |
US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
PT2736495T (en) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
TW201343201A (en) | 2012-03-06 | 2013-11-01 | Otsuka Pharma Co Ltd | Sustained release oral solid preparation |
JP6282261B2 (en) | 2012-04-18 | 2018-02-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Unauthorized use and overdose prevention pharmaceutical dosage forms |
KR20160031526A (en) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
MX371372B (en) | 2013-11-26 | 2020-01-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling. |
WO2015181059A1 (en) * | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
CN104622791A (en) * | 2015-02-13 | 2015-05-20 | 扬子江药业集团有限公司 | Dezocine oral preparation |
AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US20170296476A1 (en) * | 2016-04-15 | 2017-10-19 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
KR102380498B1 (en) * | 2021-02-24 | 2022-04-01 | 주식회사 청안오가닉스 | Composition for manufacturing sustained-release tablets capable of controlling sustained release of active ingredients in health functional food |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994276A (en) * | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
FR2729857B1 (en) * | 1995-01-27 | 1997-04-04 | Rhone Poulenc Chimie | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF SUSTAINED-RELEASE TABLETS BASED ON GRANULES OF HIGH MOLECULAR POLYSACCHARIDES |
US5904937A (en) * | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
EP1269997A1 (en) * | 1999-04-13 | 2003-01-02 | Beecham Pharmaceuticals (Pte) Limited | Unit dosage comprising amoxicillin and clavulanate |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
DK1404331T3 (en) * | 2001-07-06 | 2008-01-28 | Penwest Pharmaceuticals Co | Sustained release formulations of oxymorphone |
CN1268338C (en) * | 2001-07-06 | 2006-08-09 | 恩德制药公司 | Oral administration of 6-hydroxy-oxymorphone for use as antalgesic |
US20030091635A1 (en) * | 2001-09-26 | 2003-05-15 | Baichwal Anand R. | Opioid formulations having reduced potential for abuse |
US20060193912A1 (en) * | 2005-02-28 | 2006-08-31 | Penwest Pharmaceuticals Co. | Controlled release O-desmethylvenlafaxine formulations |
-
2006
- 2006-10-10 WO PCT/US2006/039923 patent/WO2008045060A1/en active Application Filing
- 2006-10-10 BR BRPI0621947-0A patent/BRPI0621947A2/en not_active IP Right Cessation
- 2006-10-10 EP EP06825846A patent/EP2079453A1/en not_active Withdrawn
- 2006-10-10 CN CNA2006800560384A patent/CN101578096A/en active Pending
- 2006-10-10 MX MX2009003771A patent/MX2009003771A/en unknown
- 2006-10-10 KR KR1020097007890A patent/KR20090113243A/en not_active Application Discontinuation
- 2006-10-10 AU AU2006349402A patent/AU2006349402A1/en not_active Abandoned
- 2006-10-10 JP JP2009532331A patent/JP5422388B2/en not_active Expired - Fee Related
- 2006-10-10 CA CA2652981A patent/CA2652981C/en not_active Expired - Fee Related
-
2009
- 2009-04-16 IL IL198168A patent/IL198168A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL198168A0 (en) | 2009-12-24 |
CA2652981A1 (en) | 2008-04-17 |
CA2652981C (en) | 2012-05-01 |
EP2079453A1 (en) | 2009-07-22 |
JP5422388B2 (en) | 2014-02-19 |
BRPI0621947A2 (en) | 2011-10-18 |
CN101578096A (en) | 2009-11-11 |
JP2010505949A (en) | 2010-02-25 |
WO2008045060A1 (en) | 2008-04-17 |
KR20090113243A (en) | 2009-10-29 |
AU2006349402A1 (en) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009003771A (en) | Robust sustained release formulations. | |
PL1998762T3 (en) | Solid dosage form containing a taste masked active agent | |
WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
WO2007095600A3 (en) | Disintegrable oral films | |
WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
NO20070887L (en) | Granular pharmaceutical formulation with time-limited release for oral administration, and intraoral rapid disintegrating tablet containing the preparation | |
WO2007103293A3 (en) | Ethanol-resistant sustained release formulations | |
WO2008085765A3 (en) | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | |
EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
WO2007053698A3 (en) | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms | |
MX2010000803A (en) | Formulations of nonopioid and confined opioid analgesics. | |
WO2010062688A3 (en) | Dosage form for insertion into the mouth | |
WO2007143155A3 (en) | Sustained release pharmaceutical dosage form containing phenylephrine | |
NZ592276A (en) | PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID | |
IL220722A (en) | Use of fentanyl in the preparation of a pharmaceutical composition for providing rapid onset of relief from breakthrough pain and a mucoadhesive bioerodable drug delivery device suitable for direct transmucosal administration of fentanyl | |
UA104745C2 (en) | Tamper resistant oral pharmaceutical dosage form comprising an opioid analgesic | |
IL179896A (en) | Opioid sustained release oral dosage form comprising a mixture of an opioid agonist and an opioid antagonist for use in the treatment of restless leg syndrome | |
MX350871B (en) | Chewable vehicle for mouth absorption. | |
JP2009522376A5 (en) | ||
WO2007106550A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
WO2007018588A8 (en) | Stable pharmaceutical composition comprising linezolid form iv | |
MX2009009132A (en) | Improved medicinal compositions comprising buprenorphine and naltrexone. | |
NZ628513A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
WO2007123865A3 (en) | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists | |
WO2007146805A3 (en) | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty |